Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03302234
Title Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Ipilimumab + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST